Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at BTIG Research in a note issued to investors on Tuesday, Benzinga reports. They currently have a $32.00 target price on the stock. BTIG Research’s target price suggests a potential upside of 33.00% from the company’s current price.
Other analysts also recently issued reports about the stock. Weiss Ratings downgraded shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 31st. JPMorgan Chase & Co. started coverage on shares of Kestra Medical Technologies in a research report on Monday, August 10th. They issued an “overweight” rating and a $30.00 target price for the company. Wolfe Research set a $30.00 price target on shares of Kestra Medical Technologies in a research note on Wednesday, July 15th. Oppenheimer initiated coverage on shares of Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a “market perform” rating on the stock. Finally, Wall Street Zen cut Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $28.14.
Get Our Latest Stock Report on KMTS
Kestra Medical Technologies Stock Up 5.3%
Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) last released its earnings results on Monday, September 14th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.14). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The firm had revenue of $30.97 million during the quarter. On average, sell-side analysts anticipate that Kestra Medical Technologies will post -2.29 earnings per share for the current fiscal year.
Insider Buying and Selling at Kestra Medical Technologies
In other Kestra Medical Technologies news, insider Brian Webster sold 15,000 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $27.48, for a total value of $412,200.00. Following the transaction, the insider directly owned 460,215 shares in the company, valued at $12,646,708.20. The trade was a 3.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mary Ladone sold 3,908 shares of the stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $25.20, for a total transaction of $98,481.60. Following the completion of the transaction, the director directly owned 37,507 shares in the company, valued at $945,176.40. The trade was a 9.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 239,588 shares of company stock worth $5,802,688. 5.30% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. Seven Grand Managers LLC bought a new position in Kestra Medical Technologies in the 4th quarter valued at about $2,652,000. Eventide Asset Management LLC boosted its holdings in shares of Kestra Medical Technologies by 5.4% during the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after acquiring an additional 65,288 shares during the period. Sei Investments Co. grew its position in shares of Kestra Medical Technologies by 22.6% in the first quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock valued at $4,726,000 after purchasing an additional 43,753 shares during the last quarter. UBS Group AG grew its position in shares of Kestra Medical Technologies by 34.9% in the fourth quarter. UBS Group AG now owns 270,058 shares of the company’s stock valued at $7,162,000 after purchasing an additional 69,908 shares during the last quarter. Finally, Summit Partners Public Asset Management LLC acquired a new stake in Kestra Medical Technologies during the 4th quarter worth approximately $9,282,000.
About Kestra Medical Technologies
Kestra Medical Technologies, Inc is a medical device company focused on developing and commercializing technologies for patients at risk of sudden cardiac arrest. The company’s primary product is the ASSURE wearable cardioverter defibrillator, a wearable system designed to continuously monitor a patient’s heart rhythm and deliver an electrical shock when a life-threatening arrhythmia is detected.
The ASSURE system is intended to provide temporary protection for patients who may be at elevated risk of sudden cardiac death but are not yet candidates for, or are awaiting, an implantable cardioverter-defibrillator.
Read More
- Five stocks we like better than Kestra Medical Technologies
- 3 Defense Stocks Riding the High-Energy Laser Boom
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
Receive News & Ratings for Kestra Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kestra Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
